Hemodialysis Vascular Grafts Market Size, Share & Trends Analysis Report By Raw Material (Polyester, Polytetrafluoroethylene, Polyurethane, Biological Materials), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global hemodialysis vascular grafts market size was valued at USD 189.9 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.1% from 2023 to 2030. The rising prevalence of Chronic Kidney Disease (CKD) and the need for hemodialysis as a treatment option is one of the major factors boosting the market growth.CKD is a progressive condition in which the kidneys gradually lose function over time. CKD can be caused by a variety of underlying conditions, including diabetes, hypertension, and glomerulonephritis. Also, the increasing number of people suffering from the end-stage renal disease is adding fuel to the market growth. As per the United States Renal Data System (USRDS), nearly 786,000 people in the U.S. are living with End-stage Kidney Disease (ESKD), also known as an ESRD, as of 2021 and this number is anticipated to reach 886,000 by 2030

Further, the rising geriatric population is a significant driver of the market. As per the World Health Organization, approximately 1 in 6 people will be aged 60 years or over across the globe, and by 2050, the world’s population of people aged 60 years and above will be around 2.1 billion. As people age, the risk of developing kidney disease also increases due to numerous factors such as hypertension, diabetes, and cardiovascular disease. The prevalence of kidney disease increases with age, and a majority of people with ESRD globally are over the age of 60. According to CDC, in 2021, around 38.0% of people aged 65 and above suffered from chronic kidney disease in the United States.

Technological advancements in hemodialysis vascular grafts, such as the development of biocompatible materials & improved designs, and increase durability & effectiveness of the devices, are expected to impel the market demand. One of the main technological advancements in the field is the use of biocompatible materials. These materials are designed to be compatible with the body, reducing the risk of rejection and infection. Biocompatible materials such as polytetrafluoroethylene and expanded polytetrafluoroethylene (ePTFE) have been used to create hemodialysis vascular grafts that are more durable and have a longer lifespan than traditional grafts.

The outbreak of COVID-19 had a significant impact on the hemodialysis vascular grafts market. The disrupted supply chains, during the pandemic, caused delays in the production and distribution of the grafts. In addition, elective surgeries, including those for hemodialysis vascular grafts, were put on hold in many countries which led to a decline in the revenue of the market players. However, the pandemic also resulted in an increase in the number of patients with CKD, as COVID-19 led to acute kidney injury and an increase in preexisting kidney conditions. This is expected to raise the demand for hemodialysis vascular grafts in the long term.

Raw Material Insights

By raw material, the polytetrafluoroethylene (PTFE) segment held the largest share of 47.2% in 2022. The Polytetrafluoroethylene (PTFE) hemodialysis vascular grafts have better pliability & adhesion as compared to other materials and similar patency as compared to other synthetic products. PTFE hemodialysis vascular grafts are synthetic tubes made of PTFE material used in hemodialysis to provide patients with kidney failure access to blood.

The segment is witnessing growth owing to the rising prevalence of kidney failure, technological advancements in the design, and supportive government and reimbursement policies for hemodialysis procedures, including PTFE hemodialysis vascular grafts.

Further, the segment is anticipated to grow at the fastest rate during the forecast period owing to rising funding and investments for kidney diseases and growing private sector investments in dialysis infrastructure. For instance, In August 2022, Xeltis, a Dutch medical technology company, received USD 16.0 million in investment from Grand Pharma, a Chinese firm. The startup focuses on developing devices for treating cardiovascular diseases and reducing the occurrence of CKD. The investment from Grand Pharmaceutical Group Ltd. consists of equity and a product license, marking the company's first commercial agreement and first funding from an Asian company.

Regional Insights

In 2022, North America dominated the hemodialysis vascular grafts market with a share of 29.8%. The increasing number of patients with non-communicable diseases, such as diabetes and hypertension, which lead to CKDs, is expected to promote the demand for hematology vascular access grafts in this region. Also, the incidence of renal diseases that lead to kidney failure is increasing in North America. Further, the presence of well-defined regulatory guidelines and the increase in the adoption of biological grafts are some of the factors driving the market in this region.

In addition, the surge in healthcare expenditure, advancements in healthcare infrastructure, high disposable income, and an increase in the number of dialysis centers positively affect the market demand.

 Market growth in Asia Pacific is anticipated to witness the fastest growth during the forecast period. The region has significant unmet needs for patients with ESRD and CKD, owing to the factors such as organ donation regulations, choice of an organ donor, and high cost of the treatment. Due to these factors, the number of patients undergoing hemodialysis procedures is increasing. Thus, a rise in the number of patients undergoing dialysis is expected to boost demand for hemodialysis vascular grafts in Asia Pacific.

Key Companies & Market Share Insights

Various strategies such as product development, partnerships, funding, investments, etc. adopted by the key players are driving the hemodialysis vascular graft market. For instance, in May 2022, Medtronic announced that it partnered with DaVita to improve patient outcomes and accelerate innovation in kidney care devices. The companies announced the formation of a new, separate medical device company, which will be focused on kidney care to improve overall outcomes in the field of hemodialysis and patient treatment experience. Some prominent players in the global hemodialysis vascular graft market include:

• W. L. Gore & Associates, Inc.,

• C. R. Bard, Inc.,

• Vascudyne, Inc.,

• LeMaitre,

• Getinge AB,

• VASCULAR GENESIS,

• InnAVasc Medical, Inc.

• CryoLife, Inc.

• Merit Medical Systems

• BIOVIC Sdn Bhd.

Hemodialysis Vascular Grafts Market Report Scope

Global Hemodialysis Vascular Grafts Market Segmentation

This report forecasts revenue growth at global, regional, and country levels in addition to providing an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global hemodialysis vascular grafts market report based on the raw material and region:

• Raw Material Outlook (Revenue, USD Million, 2018 - 2030)

  • Polyester

  • Polytetrafluoroethylene

  • Polyurethane

  • Biological Materials

    • Human Saphenous & Umbilical Veins

    • Tissue Engineered Materials

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait